Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003

Novadip Biosciences Reports Positive Interim…

HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer

HORAMA appoints industry veteran Ian…

Immunic, Inc. Announces Pricing of $15 Million Financing

Immunic, Inc. Announces Pricing of…

Aelin Therapeutics appoints Alexander Scheer, Ph.D., as Chief Scientific Officer

Aelin Therapeutics appoints Alexander Scheer,…

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Immunic, Inc. Reports that IMU-838,…

iTeos Therapeutics Closes $125 Million Series B2 Financing

iTeos Therapeutics Closes $125 Million…

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

eTheRNA launches an international consortium…

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

HORAMA Signs Exclusive License Agreement…

HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)

HORAMA strengthens its management team…

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

iTeos Therapeutics Initiates Phase 1/2 Study…